Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet
J. Grundy (San Diego, United States of America), A. Blackburn (San Diego, United States of America), E. Parsley (San Diego, United States of America), Y. Tang (San Diego, United States of America), C. King (San Diego, United States of America), J. Adams (San Diego, United States of America)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3037
Disease area: Pulmonary vascular diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Grundy (San Diego, United States of America), A. Blackburn (San Diego, United States of America), E. Parsley (San Diego, United States of America), Y. Tang (San Diego, United States of America), C. King (San Diego, United States of America), J. Adams (San Diego, United States of America). Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet. 3037
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: